Opolimogene capmilisbac - Janssen Biotech

Drug Profile

Opolimogene capmilisbac - Janssen Biotech

Alternative Names: ADU-741; JNJ-64041809; JNJ-809; Opolimogene-capmilisbac

Latest Information Update: 15 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aduro BioTech
  • Developer Janssen Biotech
  • Class Antineoplastics; Bacterial vaccines; Gene therapies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Epidermal growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 31 Jan 2017 Janssen Research & Development suspends enrolment in a phase I trial for Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA (NCT02625857)
  • 28 Dec 2016 Janssen Research & Development re-initiates enrolment in a phase I trial for Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA (NCT02625857)
  • 18 Nov 2016 Janssen Research & Development withdraws a phase II trial for Prostate cancer (Hormone refractory, Metastatic disease, Combination therapy) prior to enrolment in USA (IV) (NCT02906605)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top